InvestorsHub Logo
Followers 21
Posts 1996
Boards Moderated 0
Alias Born 11/26/2014

Re: None

Thursday, 02/03/2022 12:08:07 PM

Thursday, February 03, 2022 12:08:07 PM

Post# of 4159
They were excited for NMIBC at SESN First in class? NOT!!!
The Company was looking at a major catalyst in 2021, the approval of Vicineum, a potential best-in-class therapeutic for the treatment of non-muscle invasive bladder cancer (NMIBC) in the U.S. Sesen has submitted the MAA for Vicineum to the EMA in March 2021, and anticipates an EU approval in 2022. aviseanalytics.com/4-biotec...

JMO, maybe, maybe not.